γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title: Anti-PD-1 Antibody Armored γδ T Cells in the Treatment of Advanced Solid Tumors, a Phase I Clinical Trail

Status Not yet recruiting

Clinical Trial Summary

This study intends to combine the advantages of γδ T cells and PD-1 monoclonal antibody to conduct an exploratory clinical study on the safety and efficacy of PD-1 antibody armored γδ T cells (γδ T-PD-1 Ab cells) in the treatment of advanced solid tumors.

Clinical Trial Description

This is a single-center, single-arm, phase I clinical trial to evaluate the safety and efficacy of γδ T-PD-1 Ab cells in patients with advanced solid tumors without standard treatment. A typical 3+3 dose-escalation design will be used to determine the optimal dose level of γδ T-PD-1 Ab cells based on the incidence of dose-limiting toxicity (DLT). The initial infusion dose level will start from 3×10^7/kg to 3×10^8/kg in every 2 weeks. ;

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

• NCT number: NCT06404281
• Study type: Interventional
• Source: Changzhou No.2 People's Hospital
• Contact: Hua Jiang, MD
• Phone: +86-18015852711
• Email: czeyjh@njmu.edu.cn
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: June 1, 2024
• Completion date: June 1, 2026